StockMacro
Menu

UroGen Pharma

$27.65 -6.1% in 6 monthsMarket cap $1.4B

URGN on XNAS, Health Care, UroGen Pharma Ltd., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 224% to $89M while shares fell 22% in a month and short interest is 10%.

  • BadFree cash flow was negative $132M over the last 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Industry
Pharmaceutical preparations (Health Care)
Employees
291
Website
urogen.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 1 Mar 2027 (an estimate: a year ago it reported on 2 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $89.0M, net loss $1.5M.
Quarter to 31 Dec 2021: revenue $16.2M, net income -$28.5MQuarter to 31 Dec 2021: revenue $16.2M, net income -$28.5MQuarter to 31 Mar 2022: revenue $13.6M, net income -$28.4MQuarter to 31 Mar 2022: revenue $13.6M, net income -$28.4MQuarter to 30 Jun 2022: revenue $16.6M, net income -$26.7MQuarter to 30 Jun 2022: revenue $16.6M, net income -$26.7MQuarter to 30 Sep 2022: revenue $16.1M, net income -$25.8MQuarter to 30 Sep 2022: revenue $16.1M, net income -$25.8MQuarter to 31 Dec 2022: revenue $18.1M, net income -$28.9MQuarter to 31 Dec 2022: revenue $18.1M, net income -$28.9MQuarter to 31 Mar 2023: revenue $17.2M, net income -$30.2MQuarter to 31 Mar 2023: revenue $17.2M, net income -$30.2MQuarter to 30 Jun 2023: revenue $21.1M, net income -$24.1MQuarter to 30 Jun 2023: revenue $21.1M, net income -$24.1MQuarter to 30 Sep 2023: revenue $20.9M, net income -$21.9MQuarter to 30 Sep 2023: revenue $20.9M, net income -$21.9MQuarter to 31 Dec 2023: revenue $23.5M, net income -$26.0MQuarter to 31 Dec 2023: revenue $23.5M, net income -$26.0MQuarter to 31 Mar 2024: revenue $18.8M, net income -$32.3MQuarter to 31 Mar 2024: revenue $18.8M, net income -$32.3MQuarter to 30 Jun 2024: revenue $21.8M, net income -$33.4MQuarter to 30 Jun 2024: revenue $21.8M, net income -$33.4MQuarter to 30 Sep 2024: revenue $25.2M, net income -$23.7MQuarter to 30 Sep 2024: revenue $25.2M, net income -$23.7MQuarter to 31 Dec 2024: revenue $24.6M, net income -$37.5MQuarter to 31 Dec 2024: revenue $24.6M, net income -$37.5MQuarter to 31 Mar 2025: revenue $20.3M, net income -$43.8MQuarter to 31 Mar 2025: revenue $20.3M, net income -$43.8MQuarter to 30 Jun 2025: revenue $24.2M, net income -$49.9MQuarter to 30 Jun 2025: revenue $24.2M, net income -$49.9MQuarter to 30 Sep 2025: revenue $27.5M, net income -$33.3MQuarter to 30 Sep 2025: revenue $27.5M, net income -$33.3MQuarter to 31 Dec 2025: revenue $37.8M, net income -$26.4MQuarter to 31 Dec 2025: revenue $37.8M, net income -$26.4MQuarter to 31 Mar 2026: revenue $51.0M, net income -$23.6MQuarter to 31 Mar 2026: revenue $51.0M, net income -$23.6MQuarter to 30 Jun 2026: revenue $72.5M, net income -$14.4MQuarter to 30 Jun 2026: revenue $72.5M, net income -$14.4MQuarter to 30 Sep 2026: revenue $89.0M, net income -$1.5MQuarter to 30 Sep 2026: revenue $89.0M, net income -$1.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $89.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$89.0M-$1.5M
30 Jun 2026$72.5M-$14.4M
31 Mar 2026$51.0M-$23.6M
31 Dec 2025$37.8M-$26.4M
30 Sep 2025$27.5M-$33.3M
30 Jun 2025$24.2M-$49.9M
31 Mar 2025$20.3M-$43.8M
31 Dec 2024$24.6M-$37.5M
30 Sep 2024$25.2M-$23.7M
30 Jun 2024$21.8M-$33.4M
31 Mar 2024$18.8M-$32.3M
31 Dec 2023$23.5M-$26.0M
30 Sep 2023$20.9M-$21.9M
30 Jun 2023$21.1M-$24.1M
31 Mar 2023$17.2M-$30.2M
31 Dec 2022$18.1M-$28.9M
30 Sep 2022$16.1M-$25.8M
30 Jun 2022$16.6M-$26.7M
31 Mar 2022$13.6M-$28.4M
31 Dec 2021$16.2M-$28.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $250.3M $96.5M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +159% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$65.8M -$164.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 91.4% 88.0% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -12.4% -138% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -26.3% -171% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$132.0M -$138.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $91.9M $153.8M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $200.0M $122.1M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $108.1M -$31.7M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 5.4 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 5.9 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. – 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
UroGen PharmaURGN (this company) $1.4Bloss5.4+159%-26.3%
uniQureQURE $1.4Bloss67.3+28%–
Phibro Animal HealthPAHC $1.4B13.20.88+10%6.7%
Nuvation BioNUVB $1.3Bloss6.6+654%-67.4%
Rapport TherapeuticsRAPP $1.4Bloss–––
AnaptysBioANAB $1.4B7.57.2+13%96.3%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$3.0M

bought $0, sold $3.0M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+15%

214 13F filers vs 186

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

83%

40.5M shares held by 13F filers (30 Sep 2026) of 49.0M outstanding (28 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

10%

5.1M shares sold short (30 Oct 2026) of 49.0M outstanding (28 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.1

5.1M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-8.9%

5.6M shares sold short in the report before, 5.1M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

52%

52% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+224%

$89.0M vs $27.5M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$118K

the 12 months before: $205K

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$30K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

10

10 articles in the last 7 days; its usual week has 1.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.7×

10 articles in the last 7 days; its usual week has 1.5.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $89.0M, 3.2× a year earlier

Price $27.65 on 20 Nov 2026, +11% over 12 months (12-month range $17.00 to $50.29)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $4.5M in the last 12 months (the 12 months before: -$923K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.
Revenue per quarter. Revenue $89.0M in the latest quarter, +224% on a year earlier.
Capital spending per quarter. Capital spending $72K in the latest quarter, -17% on a year earlier.
Institutional holders (13F filers). 214 13F filers reported holding it in the latest 13F quarter, +42% on a year earlier.
Federal obligations. Federal obligations: $16K published in the last 12 months, -95% on the 12 months before.
Lobbying spend. Lobbying spend: $30K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
5 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 89.0M vs usual 26.3M (2026-09-30); 3.2x the same period a year earlier
6 Aug 2026Sharp changeQuarterly revenue change: quarterly revenue change, 72.5M vs usual 24.9M (2026-06-30); 3.0x the same period a year earlier
23 Jun 20268-K and other filingsDirector or officer change
23 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 May 2026Sharp changeQuarterly revenue change: quarterly revenue change, 51.0M vs usual 24.4M (2026-03-31); 2.5x the same period a year earlier
3 Mar 2026Sharp changeQuarterly revenue change: quarterly revenue change, 37.8M vs usual 23.9M (2025-12-31); 1.5x the same period a year earlier
18 Nov 2025Sharp changeShort interest spike: short interest spike, 11.3M vs usual 6.1M (2025-10-31); 1.7x the same period a year earlier
28 Oct 2025Sharp changeShort interest spike: short interest spike, 11.1M vs usual 6.1M (2025-10-15); 1.7x the same period a year earlier
14 Oct 2025Sharp changeShort interest spike: short interest spike, 8.7M vs usual 6.1M (2025-09-30); 1.2x the same period a year earlier
27 Aug 20258-K and other filingsDirector or officer change
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 37 vs usual 20.50 (2025-06-30); 1.9x the same period a year earlier
3 Jul 20258-K and other filingsDirector or officer change
3 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Oct 20248-K and other filingsDirector or officer change
13 Sep 20248-K and other filingsDirector or officer change
8 Aug 20248-K and other filingsDirector or officer change
8 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Jan 2024Sharp changeShort interest spike: short interest spike, 3.4M vs usual 979K (2024-01-12); 6.0x the same period a year earlier
16 Jan 2024Sharp changeShort interest spike: short interest spike, 3.5M vs usual 927K (2023-12-29); 5.3x the same period a year earlier
2 Jan 2024Sharp changeShort interest spike: short interest spike, 3.1M vs usual 881K (2023-12-15); 4.6x the same period a year earlier
12 Dec 2023Sharp changeShort interest spike: short interest spike, 2.9M vs usual 798K (2023-11-30); 4.3x the same period a year earlier
28 Nov 2023Sharp changeShort interest spike: short interest spike, 2.8M vs usual 737K (2023-11-15); 4.2x the same period a year earlier
14 Nov 2023Sharp changeShort interest spike: short interest spike, 2.3M vs usual 737K (2023-10-31); 3.0x the same period a year earlier
31 Oct 2023Sharp changeShort interest spike: short interest spike, 1.6M vs usual 737K (2023-10-13); 1.5x the same period a year earlier
11 Sep 20238-K and other filingsDirector or officer change
29 Aug 2023Sharp changeShort interest spike: short interest spike, 1.7M vs usual 737K (2023-08-15); 1.1x the same period a year earlier
15 Aug 2023Sharp changeShort interest spike: short interest spike, 1.6M vs usual 737K (2023-07-31); 1.1x the same period a year earlier
15 Aug 2023Sharp changeMany funds opening a new position: many funds opening a new position, 29 vs usual 7.50 (2023-06-30); 3.6x the same period a year earlier
14 Aug 20238-K and other filingsPrivate placement of securities (Form D)
25 Jul 20238-K and other filingsDirector or officer change
25 Jul 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Nov 20228-K and other filingsDirector or officer change
12 Sep 20228-K and other filingsDirector or officer change
12 Sep 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Jul 2022Lobbying filinglobbying engagement terminated (BAKER & HOSTETLER LLP)
14 Jul 2022Lobbying filingnew lobbying registration (BGR GOVERNMENT AFFAIRS)
13 Jun 20228-K and other filingsDirector or officer change
21 Mar 20228-K and other filingsDirector or officer change
21 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$77K published
Month from 1 Jan 2022: -$431K published
Month from 1 Feb 2022: -$78K published
Month from 1 May 2022: -$2K published
Month from 1 Aug 2022: -$2K published
Month from 1 Sep 2022: -$26K published
Month from 1 Nov 2022: -$3K published
Month from 1 Feb 2023: -$36K published
Month from 1 Sep 2023: -$68K published
Month from 1 Feb 2024: -$138K published
Month from 1 Mar 2024: -$169K published
Month from 1 Jun 2024: -$67K published
Month from 1 Sep 2024: -$31K published
Month from 1 Feb 2025: -$133K published
Month from 1 Jun 2025: -$38K published
Month from 1 Jul 2025: -$243K published
Month from 1 Aug 2025: -$177K published
Month from 1 Sep 2025: -$46K published
Month from 1 Oct 2025: -$37K published
Month from 1 Nov 2025: -$250K published
Month from 1 Feb 2026: -$292K published
Month from 1 May 2026: -$300K published
Month from 1 Jun 2026: -$493K published
Month from 1 Jul 2026: -$400K published
Month from 1 Aug 2026: -$2.9M published
Month from 1 Sep 2026: -$102K published
Month from 1 Oct 2026: -$81K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $16.2M, +103% on a year earlier; public on 22 Mar 2022
Quarter ended 31 Mar 2022: $13.6M, +81% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $16.6M, +27% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $16.1M, +42% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $18.1M, +12% on a year earlier; public on 25 Mar 2023
Quarter ended 31 Mar 2023: $17.2M, +27% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $21.1M, +27% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $20.9M, +30% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $23.5M, +30% on a year earlier; public on 11 Mar 2025
Quarter ended 31 Mar 2024: $18.8M, +9.2% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $21.8M, +3.4% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $25.2M, +21% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $24.6M, +4.4% on a year earlier; public on 11 Mar 2025
Quarter ended 31 Mar 2025: $20.3M, +7.8% on a year earlier; public on 13 May 2025
Quarter ended 30 Jun 2025: $24.2M, +11% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $27.5M, +9.0% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $37.8M, +54% on a year earlier; public on 3 Mar 2026
Quarter ended 31 Mar 2026: $51.0M, +152% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $72.5M, +199% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $89.0M, +224% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $202K, +17% on a year earlier; public on 22 Mar 2022
Quarter ended 31 Mar 2022: $25K, -91% on a year earlier; public on 11 May 2022
Quarter ended 30 Jun 2022: $63K, -8.7% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $153K, -21% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $13K, -94% on a year earlier; public on 25 Mar 2023
Quarter ended 31 Mar 2023: $23K, -8.0% on a year earlier; public on 12 May 2023
Quarter ended 30 Jun 2023: $15K, -76% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $100K, -35% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Dec 2023: $56K, +331% on a year earlier; public on 15 Mar 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $84K, +460% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $96K, -4.0% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $115K, +105% on a year earlier; public on 11 Mar 2025
Quarter ended 31 Mar 2025: $44K; public on 13 May 2025
Quarter ended 30 Jun 2025: $141K, +68% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $87K, -9.4% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $17K, -85% on a year earlier; public on 3 Mar 2026
Quarter ended 31 Mar 2026: $54K, +23% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $60K, -57% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $72K, -17% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 71; public on 14 Feb 2022
31 Mar 2022 report: 81; public on 16 May 2022
30 Jun 2022 report: 65; public on 15 Aug 2022
30 Sep 2022 report: 54; public on 14 Nov 2022
31 Dec 2022 report: 60; public on 14 Feb 2023
31 Mar 2023 report: 63; public on 15 May 2023
30 Jun 2023 report: 82; public on 14 Aug 2023
30 Sep 2023 report: 96; public on 14 Nov 2023
31 Dec 2023 report: 99; public on 14 Feb 2024
31 Mar 2024 report: 110; public on 15 May 2024
30 Jun 2024 report: 111; public on 14 Aug 2024
30 Sep 2024 report: 125; public on 14 Nov 2024
31 Dec 2024 report: 137; public on 14 Feb 2025
31 Mar 2025 report: 138; public on 15 May 2025
30 Jun 2025 report: 144; public on 14 Aug 2025
30 Sep 2025 report: 151; public on 14 Nov 2025
31 Dec 2025 report: 162; public on 17 Feb 2026
31 Mar 2026 report: 165; public on 15 May 2026
30 Jun 2026 report: 186; public on 14 Aug 2026
30 Sep 2026 report: 214; public on 16 Nov 2026
Federal obligations
Month from 1 Jun 2023: $390K published
Month from 1 Mar 2024: $99K published
Month from 1 Apr 2024: $99K published
Month from 1 Jun 2024: -$99K published
Month from 1 Feb 2025: $99K published
Month from 1 Apr 2025: $106K published
Month from 1 Sep 2025: $102K published
Month from 1 Dec 2025: $33K published
Month from 1 Jan 2026: -$17K published
Lobbying spend
Quarter from 1 Jan 2022: $40K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $60K published
Quarter from 1 Oct 2026: $30K published

What is unusual now

  • Made public in the last 90 days: it reported revenue of $89.0M for the quarter ended 30 Sep 2026, 3.2× the same quarter last year.
  • Quarterly revenue change: reported revenue of $89.0M for the quarter ended 30 Sep 2026, 3.2× the same quarter last year Public on 5 Nov 2026.
  • Insider net buying (open market): Insiders sold a net $4.5M in the last 12 months (the 12 months before: -$923K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 86 insider trades

Last 90 days: 3 sales, $183K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
9 Oct 2026Chris DegnanChief Financial OfficerSellafter exercising options2,202$36.69$81KForm 4
9 Sep 2026Jason Drew SmithGeneral CounselSellafter exercising options1,519$42.54$65KForm 4
9 Sep 2026Mark SchoenbergChief Medical OfficerSellafter exercising options871$42.92$37KForm 4
24 Aug 2026Mark SchoenbergChief Medical OfficerSell60,677$47.05$2.9MForm 4
10 Jul 2026Mark SchoenbergChief Medical OfficerSellplanned in advance (10b5-1)10,000$40.00$400KForm 4
24 Jun 2026Mark SchoenbergChief Medical OfficerSellplanned in advance (10b5-1)10,000$35.01$350KForm 4
9 Jun 2026Mark SchoenbergChief Medical OfficerSellafter exercising options5,222$27.30$143KForm 4
11 May 2026Mark SchoenbergChief Medical OfficerSellplanned in advance (10b5-1)10,000$30.00$300KForm 4

214 institutions reported shares at the end of Q3 2026, 83% of the shares outstanding; 46 opened a position, 16 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
RTW Investments, LP4.5M9.26%$184.6MNo change
BlackRock, Inc.3.1M6.34%$126.3M-93K-2.9%
Kynam Capital Management, LP2.4M4.96%$98.9MNo change
Jefferies Financial Group Inc.2.2M4.48%$89.4MNo change
Morgan Stanley2.2M4.43%$88.4M-402K-16%
Acorn Capital Advisors, LLC1.6M3.36%$67.0M-25K-1.5%
Opaleye Management Inc.1.4M2.94%$58.5MNo change
American Century Companies Inc1.4M2.80%$55.9M-310K-18%
D. E. Shaw & Co., Inc.1.3M2.62%$52.2M+138K+12%
Silverarc Capital Management, LLC1.1M2.34%$46.7M-153K-12%

Company events

All 31 company events

In 12 months: 1 major agreement, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
23 Jun 2026Director or officer changeSame filing: changed shareholder rights, shareholder vote results8-K
2 Mar 2026Signed a major agreementSame filing: took on new debt8-K
27 Aug 2025Director or officer changeSame filing: shareholder vote results8-K
3 Jul 2025Director or officer change8-K
20 Feb 2025Signed a major agreementSame filing: sold shares privately8-K
9 Oct 2024Director or officer change8-K
13 Sep 2024Director or officer change8-K
8 Aug 2024Director or officer changeSame filing: shareholder vote results8-K

Reported lobbying spend: $30K in Q3 2026, $60K in Q2 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2022EndedBaker & Hostetler LLPfor Urogen Pharma Ltd.Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.Health issuesFiling
1 Jun 2022NewBGR Government Affairsfor Urogen Pharma, Inc.Provide strategic counsel and advocacy for issues related to cancer and urologic disease treatments and regulatory reimbursement policy around requirement for manufacturers to provide refunds to Medicare for discarded amounts.Health issuesFiling
15 Mar 2020NewBaker & Hostetler LLPfor Urogen Pharma Ltd.Regulatory and reimbursement policy issues related to federal healthcare programs, including Medicare and Medicaid.Health issuesFiling

The 5 newest of 100 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 Aug 2023confirmed

Confirmed across sources Institutional holdings and Short interest and volume

UroGen Pharma (URGN): saw 29 13F filers open a new position in the quarter ended 30 Jun 2023, 3.6× the same quarter last year, while it had 1.7M shares sold short in the 15 Aug 2023 report, 1.1× the same report last year. Two unrelated kinds of activity within 14 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2023
  • Short interest and volume: Short interest spike, became public on 10 Aug 2023
  • Short interest and volume: Short interest spike, became public on 25 Aug 2023
2021-06-30: 72021-09-30: 112021-12-31: 32022-03-31: 122022-06-30: 82022-09-30: 42022-12-31: 82023-03-31: 62023-06-30: 29
The quarter ended 30 Jun 2023 against the 8 quarters before it. this quarterearliernormal: 7.5
See the evidence (3 changes)

Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

UroGen Pharma saw 29 13F filers open a new position in the quarter ended 30 Jun 2023, 3.6× the same quarter last year.

This period
29 (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
7.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+5.8
Same quarter last year
8
History used
2,191 days
2021-06-30: 72021-09-30: 112021-12-31: 32022-03-31: 122022-06-30: 82022-09-30: 42022-12-31: 82023-03-31: 62023-06-30: 29
the quarter ended 30 Jun 20238 earlier quartersnormal: 7.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 10 Aug 2023

UroGen Pharma had 1.6M shares sold short in the 31 Jul 2023 report, 1.1× the same report last year.

This period
1.6M (the 31 Jul 2023 report)
Normal report (median of 24 earlier)
737K
Typical spread (median absolute deviation)
152K
How far from its usual level
+3.7
Same report last year
1.5M
History used
2,040 days
2022-07-29: 1.5M2022-08-15: 1.5M2022-08-31: 1.4M2022-09-15: 1.4M2022-09-30: 1.4M2022-10-14: 1.1M2022-10-31: 751K2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M
the 31 Jul 2023 report24 earlier reportsnormal: 737K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Aug 2023

UroGen Pharma had 1.7M shares sold short in the 15 Aug 2023 report, 1.1× the same report last year.

This period
1.7M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
737K
Typical spread (median absolute deviation)
152K
How far from its usual level
+4.1
Same report last year
1.5M
History used
2,055 days
2022-08-15: 1.5M2022-08-31: 1.4M2022-09-15: 1.4M2022-09-30: 1.4M2022-10-14: 1.1M2022-10-31: 751K2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M
the 15 Aug 2023 report24 earlier reportsnormal: 737K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 5 Nov 2026Financials change

    reported revenue of $89.0M for the quarter ended 30 Sep 2026, 3.2× the same quarter last year.

    Same quarter last year: $27.5M; its normal quarter is $26.3M.

    See the evidence
    This period
    $89.0M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $26.3M
    Typical spread (median absolute deviation)
    $4.1M
    How far from its usual level
    +10.3
    Same quarter last year
    $27.5M
    History used
    3,470 days
    2024-09-30: $25.2M2024-12-31: $24.6M2025-03-31: $20.3M2025-06-30: $24.2M2025-09-30: $27.5M2025-12-31: $37.8M2026-03-31: $51.0M2026-06-30: $72.5M2026-09-30: $89.0M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $26.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 6 Aug 2026Financials change

    reported revenue of $72.5M for the quarter ended 30 Jun 2026, 3.0× the same quarter last year.

    Same quarter last year: $24.2M; its normal quarter is $24.9M.

    See the evidence
    This period
    $72.5M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $24.9M
    Typical spread (median absolute deviation)
    $2.8M
    How far from its usual level
    +11.4
    Same quarter last year
    $24.2M
    History used
    3,378 days
    2024-06-30: $21.8M2024-09-30: $25.2M2024-12-31: $24.6M2025-03-31: $20.3M2025-06-30: $24.2M2025-09-30: $27.5M2025-12-31: $37.8M2026-03-31: $51.0M2026-06-30: $72.5M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $24.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  3. 23 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 23 Jun 2026Filings record

    Director or officer change

  5. 7 May 2026Financials change

    reported revenue of $51.0M for the quarter ended 31 Mar 2026, 2.5× the same quarter last year.

    Same quarter last year: $20.3M; its normal quarter is $24.4M.

    See the evidence
    This period
    $51.0M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $24.4M
    Typical spread (median absolute deviation)
    $2.8M
    How far from its usual level
    +6.4
    Same quarter last year
    $20.3M
    History used
    3,287 days
    2024-03-31: $18.8M2024-06-30: $21.8M2024-09-30: $25.2M2024-12-31: $24.6M2025-03-31: $20.3M2025-06-30: $24.2M2025-09-30: $27.5M2025-12-31: $37.8M2026-03-31: $51.0M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $24.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  6. 3 Mar 2026Financials change

    reported revenue of $37.8M for the quarter ended 31 Dec 2025, 1.5× the same quarter last year.

    Same quarter last year: $24.6M; its normal quarter is $23.9M.

    See the evidence
    This period
    $37.8M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $23.9M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    +5.6
    Same quarter last year
    $24.6M
    History used
    3,197 days
    2023-12-31: $23.5M2024-03-31: $18.8M2024-06-30: $21.8M2024-09-30: $25.2M2024-12-31: $24.6M2025-03-31: $20.3M2025-06-30: $24.2M2025-09-30: $27.5M2025-12-31: $37.8M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $23.9M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  7. 13 Nov 2025Short interest and volume change

    had 11.3M shares sold short in the 31 Oct 2025 report, 1.7× the same report last year.

    Same report last year: 6.6M; its normal report is 6.1M.

    See the evidence
    This period
    11.3M (the 31 Oct 2025 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    518K
    How far from its usual level
    +6.7
    Same report last year
    6.6M
    History used
    2,863 days
    2024-10-31: 6.6M2024-11-15: 6.4M2024-11-29: 5.8M2024-12-13: 5.8M2024-12-31: 5.8M2025-01-15: 6.0M2025-01-31: 6.2M2025-02-14: 6.2M2025-02-28: 6.1M2025-03-14: 6.2M2025-03-31: 5.7M2025-04-15: 5.1M2025-04-30: 5.0M2025-05-15: 5.6M2025-05-30: 3.9M2025-06-13: 6.1M2025-06-30: 5.5M2025-07-15: 7.3M2025-07-31: 7.2M2025-08-15: 6.9M2025-08-29: 7.0M2025-09-15: 7.9M2025-09-30: 8.7M2025-10-15: 11.1M2025-10-31: 11.3M
    the 31 Oct 2025 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 25 Oct 2025Short interest and volume change

    had 11.1M shares sold short in the 15 Oct 2025 report, 1.7× the same report last year.

    Same report last year: 6.5M; its normal report is 6.1M.

    See the evidence
    This period
    11.1M (the 15 Oct 2025 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    473K
    How far from its usual level
    +7.1
    Same report last year
    6.5M
    History used
    2,847 days
    2024-10-15: 6.5M2024-10-31: 6.6M2024-11-15: 6.4M2024-11-29: 5.8M2024-12-13: 5.8M2024-12-31: 5.8M2025-01-15: 6.0M2025-01-31: 6.2M2025-02-14: 6.2M2025-02-28: 6.1M2025-03-14: 6.2M2025-03-31: 5.7M2025-04-15: 5.1M2025-04-30: 5.0M2025-05-15: 5.6M2025-05-30: 3.9M2025-06-13: 6.1M2025-06-30: 5.5M2025-07-15: 7.3M2025-07-31: 7.2M2025-08-15: 6.9M2025-08-29: 7.0M2025-09-15: 7.9M2025-09-30: 8.7M2025-10-15: 11.1M
    the 15 Oct 2025 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 10 Oct 2025Short interest and volume change

    had 8.7M shares sold short in the 30 Sep 2025 report, 1.2× the same report last year.

    Same report last year: 7.1M; its normal report is 6.1M.

    See the evidence
    This period
    8.7M (the 30 Sep 2025 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    473K
    How far from its usual level
    +3.7
    Same report last year
    7.1M
    History used
    2,832 days
    2024-09-30: 7.1M2024-10-15: 6.5M2024-10-31: 6.6M2024-11-15: 6.4M2024-11-29: 5.8M2024-12-13: 5.8M2024-12-31: 5.8M2025-01-15: 6.0M2025-01-31: 6.2M2025-02-14: 6.2M2025-02-28: 6.1M2025-03-14: 6.2M2025-03-31: 5.7M2025-04-15: 5.1M2025-04-30: 5.0M2025-05-15: 5.6M2025-05-30: 3.9M2025-06-13: 6.1M2025-06-30: 5.5M2025-07-15: 7.3M2025-07-31: 7.2M2025-08-15: 6.9M2025-08-29: 7.0M2025-09-15: 7.9M2025-09-30: 8.7M
    the 30 Sep 2025 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 27 Aug 2025Filings record

    Director or officer change

  11. 14 Aug 2025Institutional holdings change

    saw 37 13F filers open a new position in the quarter ended 30 Jun 2025, 1.9× the same quarter last year.

    Same quarter last year: 20; its normal quarter is 20.5.

    See the evidence
    This period
    37 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    20.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +5.5
    Same quarter last year
    20
    History used
    2,922 days
    2023-06-30: 292023-09-30: 222023-12-31: 122024-03-31: 172024-06-30: 202024-09-30: 222024-12-31: 212025-03-31: 192025-06-30: 37
    the quarter ended 30 Jun 20258 earlier quartersnormal: 20.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  12. 3 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 3 Jul 2025Filings record

    Director or officer change

  14. 9 Oct 2024Filings record

    Director or officer change

  15. 13 Sep 2024Filings record

    Director or officer change

  16. 8 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 8 Aug 2024Filings record

    Director or officer change

  18. 25 Jan 2024Short interest and volume change

    had 3.4M shares sold short in the 12 Jan 2024 report, 6.0× the same report last year.

    Same report last year: 570K; its normal report is 979K.

    See the evidence
    This period
    3.4M (the 12 Jan 2024 report)
    Normal report (median of 24 earlier)
    979K
    Typical spread (median absolute deviation)
    406K
    How far from its usual level
    +4.0
    Same report last year
    570K
    History used
    2,205 days
    2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M2023-08-31: 1.4M2023-09-15: 1.3M2023-09-29: 1.4M2023-10-13: 1.6M2023-10-31: 2.3M2023-11-15: 2.8M2023-11-30: 2.9M2023-12-15: 3.1M2023-12-29: 3.5M2024-01-12: 3.4M
    the 12 Jan 2024 report24 earlier reportsnormal: 979K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 11 Jan 2024Short interest and volume change

    had 3.5M shares sold short in the 29 Dec 2023 report, 5.3× the same report last year.

    Same report last year: 672K; its normal report is 927K.

    See the evidence
    This period
    3.5M (the 29 Dec 2023 report)
    Normal report (median of 24 earlier)
    927K
    Typical spread (median absolute deviation)
    354K
    How far from its usual level
    +5.0
    Same report last year
    672K
    History used
    2,191 days
    2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M2023-08-31: 1.4M2023-09-15: 1.3M2023-09-29: 1.4M2023-10-13: 1.6M2023-10-31: 2.3M2023-11-15: 2.8M2023-11-30: 2.9M2023-12-15: 3.1M2023-12-29: 3.5M
    the 29 Dec 2023 report24 earlier reportsnormal: 927K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  20. 28 Dec 2023Short interest and volume change

    had 3.1M shares sold short in the 15 Dec 2023 report, 4.6× the same report last year.

    Same report last year: 673K; its normal report is 881K.

    See the evidence
    This period
    3.1M (the 15 Dec 2023 report)
    Normal report (median of 24 earlier)
    881K
    Typical spread (median absolute deviation)
    296K
    How far from its usual level
    +5.0
    Same report last year
    673K
    History used
    2,177 days
    2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M2023-08-31: 1.4M2023-09-15: 1.3M2023-09-29: 1.4M2023-10-13: 1.6M2023-10-31: 2.3M2023-11-15: 2.8M2023-11-30: 2.9M2023-12-15: 3.1M
    the 15 Dec 2023 report24 earlier reportsnormal: 881K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 12 Dec 2023Short interest and volume change

    had 2.9M shares sold short in the 30 Nov 2023 report, 4.3× the same report last year.

    Same report last year: 673K; its normal report is 798K.

    See the evidence
    This period
    2.9M (the 30 Nov 2023 report)
    Normal report (median of 24 earlier)
    798K
    Typical spread (median absolute deviation)
    210K
    How far from its usual level
    +6.8
    Same report last year
    673K
    History used
    2,162 days
    2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M2023-08-31: 1.4M2023-09-15: 1.3M2023-09-29: 1.4M2023-10-13: 1.6M2023-10-31: 2.3M2023-11-15: 2.8M2023-11-30: 2.9M
    the 30 Nov 2023 report24 earlier reportsnormal: 798K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 28 Nov 2023Short interest and volume change

    had 2.8M shares sold short in the 15 Nov 2023 report, 4.2× the same report last year.

    Same report last year: 680K; its normal report is 737K.

    See the evidence
    This period
    2.8M (the 15 Nov 2023 report)
    Normal report (median of 24 earlier)
    737K
    Typical spread (median absolute deviation)
    164K
    How far from its usual level
    +8.6
    Same report last year
    680K
    History used
    2,147 days
    2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M2023-08-31: 1.4M2023-09-15: 1.3M2023-09-29: 1.4M2023-10-13: 1.6M2023-10-31: 2.3M2023-11-15: 2.8M
    the 15 Nov 2023 report24 earlier reportsnormal: 737K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 10 Nov 2023Short interest and volume change

    had 2.3M shares sold short in the 31 Oct 2023 report, 3.0× the same report last year.

    Same report last year: 751K; its normal report is 737K.

    See the evidence
    This period
    2.3M (the 31 Oct 2023 report)
    Normal report (median of 24 earlier)
    737K
    Typical spread (median absolute deviation)
    152K
    How far from its usual level
    +6.9
    Same report last year
    751K
    History used
    2,132 days
    2022-10-31: 751K2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M2023-08-31: 1.4M2023-09-15: 1.3M2023-09-29: 1.4M2023-10-13: 1.6M2023-10-31: 2.3M
    the 31 Oct 2023 report24 earlier reportsnormal: 737K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 25 Oct 2023Short interest and volume change

    had 1.6M shares sold short in the 13 Oct 2023 report, 1.5× the same report last year.

    Same report last year: 1.1M; its normal report is 737K.

    See the evidence
    This period
    1.6M (the 13 Oct 2023 report)
    Normal report (median of 24 earlier)
    737K
    Typical spread (median absolute deviation)
    152K
    How far from its usual level
    +4.0
    Same report last year
    1.1M
    History used
    2,114 days
    2022-10-14: 1.1M2022-10-31: 751K2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M2023-08-31: 1.4M2023-09-15: 1.3M2023-09-29: 1.4M2023-10-13: 1.6M
    the 13 Oct 2023 report24 earlier reportsnormal: 737K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 11 Sep 2023Filings record

    Director or officer change

  26. 25 Aug 2023Short interest and volume change

    had 1.7M shares sold short in the 15 Aug 2023 report, 1.1× the same report last year.

    Same report last year: 1.5M; its normal report is 737K.

    See the evidence
    This period
    1.7M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    737K
    Typical spread (median absolute deviation)
    152K
    How far from its usual level
    +4.1
    Same report last year
    1.5M
    History used
    2,055 days
    2022-08-15: 1.5M2022-08-31: 1.4M2022-09-15: 1.4M2022-09-30: 1.4M2022-10-14: 1.1M2022-10-31: 751K2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M
    the 15 Aug 2023 report24 earlier reportsnormal: 737K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  27. 15 Aug 2023several at once

    saw 29 13F filers open a new position in the quarter ended 30 Jun 2023, 3.6× the same quarter last year, while it had 1.7M shares sold short in the 15 Aug 2023 report, 1.1× the same report last year. Two unrelated kinds of activity within 14 days.

    See the evidence (3 changes)

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2023

    UroGen Pharma saw 29 13F filers open a new position in the quarter ended 30 Jun 2023, 3.6× the same quarter last year.

    This period
    29 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +5.8
    Same quarter last year
    8
    History used
    2,191 days
    2021-06-30: 72021-09-30: 112021-12-31: 32022-03-31: 122022-06-30: 82022-09-30: 42022-12-31: 82023-03-31: 62023-06-30: 29
    the quarter ended 30 Jun 20238 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 10 Aug 2023

    UroGen Pharma had 1.6M shares sold short in the 31 Jul 2023 report, 1.1× the same report last year.

    This period
    1.6M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    737K
    Typical spread (median absolute deviation)
    152K
    How far from its usual level
    +3.7
    Same report last year
    1.5M
    History used
    2,040 days
    2022-07-29: 1.5M2022-08-15: 1.5M2022-08-31: 1.4M2022-09-15: 1.4M2022-09-30: 1.4M2022-10-14: 1.1M2022-10-31: 751K2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M
    the 31 Jul 2023 report24 earlier reportsnormal: 737K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Aug 2023

    UroGen Pharma had 1.7M shares sold short in the 15 Aug 2023 report, 1.1× the same report last year.

    This period
    1.7M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    737K
    Typical spread (median absolute deviation)
    152K
    How far from its usual level
    +4.1
    Same report last year
    1.5M
    History used
    2,055 days
    2022-08-15: 1.5M2022-08-31: 1.4M2022-09-15: 1.4M2022-09-30: 1.4M2022-10-14: 1.1M2022-10-31: 751K2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M2023-08-15: 1.7M
    the 15 Aug 2023 report24 earlier reportsnormal: 737K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  28. 14 Aug 2023Institutional holdings change

    saw 29 13F filers open a new position in the quarter ended 30 Jun 2023, 3.6× the same quarter last year.

    Same quarter last year: 8; its normal quarter is 7.5.

    See the evidence
    This period
    29 (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +5.8
    Same quarter last year
    8
    History used
    2,191 days
    2021-06-30: 72021-09-30: 112021-12-31: 32022-03-31: 122022-06-30: 82022-09-30: 42022-12-31: 82023-03-31: 62023-06-30: 29
    the quarter ended 30 Jun 20238 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  29. 14 Aug 2023Filings record

    Private placement of securities (Form D)

  30. 10 Aug 2023Short interest and volume change

    had 1.6M shares sold short in the 31 Jul 2023 report, 1.1× the same report last year.

    Same report last year: 1.5M; its normal report is 737K.

    See the evidence
    This period
    1.6M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    737K
    Typical spread (median absolute deviation)
    152K
    How far from its usual level
    +3.7
    Same report last year
    1.5M
    History used
    2,040 days
    2022-07-29: 1.5M2022-08-15: 1.5M2022-08-31: 1.4M2022-09-15: 1.4M2022-09-30: 1.4M2022-10-14: 1.1M2022-10-31: 751K2022-11-15: 680K2022-11-30: 673K2022-12-15: 673K2022-12-30: 672K2023-01-13: 570K2023-01-31: 570K2023-02-15: 577K2023-02-28: 593K2023-03-15: 625K2023-03-31: 640K2023-04-14: 744K2023-04-28: 730K2023-05-15: 945K2023-05-31: 852K2023-06-15: 656K2023-06-30: 909K2023-07-14: 1.0M2023-07-31: 1.6M
    the 31 Jul 2023 report24 earlier reportsnormal: 737K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 25 Jul 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 25 Jul 2023Filings record

    Director or officer change

  33. 9 Nov 2022Filings record

    Director or officer change

  34. 12 Sep 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  35. 12 Sep 2022Filings record

    Director or officer change

  36. 19 Jul 2022Lobbying record

    UROGEN PHARMA LTD.: lobbying engagement terminated (BAKER & HOSTETLER LLP) (dated 30 Jun 2022)

  37. 14 Jul 2022Lobbying record

    UROGEN PHARMA, INC.: new lobbying registration (BGR GOVERNMENT AFFAIRS) (dated 1 Jun 2022)

  38. 13 Jun 2022Filings record

    Director or officer change

  39. 21 Mar 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 21 Mar 2022Filings record

    Director or officer change

Showing the newest 40 of 70 entries; narrow the window or the kind of data to see older ones.

Not listed: 175 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001668243
Ticker
URGN
Domain
urogen.com
Employer name
UroGen Pharma, Inc. (1 unverified)
Hq location
L3|RA'ANANA|43650 (1 unverified)
Lobbying client
urogen pharma
Name
UroGen Pharma Ltd.
Uei
L325MZRRKTJ3, L3U3BFJL3Z81
  • DOL H-1B labor condition applications and PERM certifications6 data points9 May 2022 to 23 May 2022
  • Federal lobbying disclosures (LDA)3 records, 33 data points15 Mar 2020 to 30 Sep 2026
  • SEC Form 13F institutional holdings342 data points30 Jun 2017 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)119 records15 Mar 2018 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)681 data points31 Dec 2014 to 28 Oct 2026
  • SEC Form 4 insider transactions86 records, 252 data points29 Nov 2017 to 9 Oct 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards39 data points7 Jun 2023 to 22 Jan 2026